Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Francesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, Massimo Breccia, Roberto Latagliata, Bruno Martino, Nicola Polverelli, Elisabetta Abruzzese, Mario Tiribelli, Maura Nicolosi, Micaela Bergamaschi, Alessia Tieghi, Alessandra Iurlo, Nicola Sgherza, Francesco Cavazzini, Alessandro Isidori, Gianni Binotto, Adalberto Ibatici, Monica Crugnola, Florian HeidelCostanza Bosi, Daniela Bartoletti, Giuseppe Auteri, Lucia Catani, Antonio Cuneo, Franco Aversa, Gianpietro Semenzato, Michele Cavo, Nicola Vianelli, Giulia Benevolo

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)86-88
Number of pages3
JournalLeukemia Research
Volume74
DOIs
Publication statusPublished - Nov 2018

Cite this

Palandri, F., Palumbo, G. A., Bonifacio, M., Breccia, M., Latagliata, R., Martino, B., Polverelli, N., Abruzzese, E., Tiribelli, M., Nicolosi, M., Bergamaschi, M., Tieghi, A., Iurlo, A., Sgherza, N., Cavazzini, F., Isidori, A., Binotto, G., Ibatici, A., Crugnola, M., ... Benevolo, G. (2018). Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 74, 86-88. https://doi.org/10.1016/j.leukres.2018.10.001